Catalyst
Slingshot members are tracking this event:
Teva to complete phase 3 trial for SD-809 as a treatment for Chorea Associated With Huntington Disease in December 2015 (via Aspex acquisition)
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2016
Occurred Source:
http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2157814
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Sd-809, Chorea Associated With Huntington Disease, Phase Iii
